Skip to content

The effect of addition of meperidine to intrathecal bupivacaine on postoperative pain after cesarean section.

Evaluation of the effect of addition of 5 mg meperidine to 10 mg bupivacaine for spinal anesthesia on postoperative pain in cesarean section surgery.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015052821383N2
Enrollment
40
Registered
2016-03-20
Start date
2015-02-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean section. Maternal care related to the fetus and amniotic cavity and possible delivery problems

Interventions

Intervention 1: Intrathecal injection of 0.5% hyperbaric bupivacaine 2.0 ml plus normal saline 0.5 ml. Intervention 2: Intrathecal injection of 0.5% hyperbaric bupivacaine 2.0 ml plus 1% meperidine 0.
Prevention
Intrathecal injection of 0.5% hyperbaric bupivacaine 2.0 ml plus normal saline 0.5 ml
Intrathecal injection of 0.5% hyperbaric bupivacaine 2.0 ml plus 1% meperidine 0.5 ml

Sponsors

Birjand University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: all patients 20-50 years with score 1-2 according to American Society of Anesthesia classification for risk of anesthesia were scheduled for cesarean section under spinal anesthesia. Exclusion criteria: pre-existing or pregnancy-induced hypertension, known fetal abnormality or allergy to bupivacain or mepridine.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Postoperative pain. Timepoint: Immediately after surgery, 2, 12, 24 hours after surgery. Method of measurement: Visual analog score of pain.

Secondary

MeasureTime frame
Intraoperative nausea and vomiting. Timepoint: Intraoperative. Method of measurement: Incidence of vomiting or need for administration of antiemetic drug.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Amir Saber Tanha

Birjand University of Medical Sciences

amirsaber63@gmail.com+98 56 3244 3001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026